THC therapy tanks in PhI, sending Zynerba's stock tumbling yet again
Zynerba’s stock $ZYNE is getting crushed yet again after news that its THC therapy has flopped in a Phase I trial. At least this time …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
